How Safe Is Amgen's Dividend?
(NASDAQ: AMGN) has been grabbing headlines lately, and not always for the right reasons. The company is currently engaged in a battle with the U.S. Food and Drug Administration (FDA), which has demanded that the biotech pull Tavneos, a medicine for severe anti-neutrophil cytoplasmic autoantibody-associated vasculitis (a group of rare autoimmune inflammatory diseases), from the market. The FDA is claiming that Amgen manipulated clinical trial data.
Elsewhere, Amgen has been fighting off attempts by Colorado regulators to cap the annual price of its famous psoriatic arthritis drug, Enbrel. Amgen recently won a court victory in that battle, although it probably isn't completely over yet. With all that going on, some might worry about Amgen's business and ability to maintain its dividend program intact. Should investors seek out other dividend stocks?
Image source: The Motley Fool.
Source Fool.com
Amgen Inc. Aktie
Die Aktie ist durchaus ein Favorit unsere Community mit 36 Buy-Einschätzungen und 3 Sell-Einschätzungen.
Ein positives, wenn auch nicht starkes, Potenzial für Amgen Inc. mit einem Kursziel von 327 € im Vergleich zu 309.9 €.
